Grifols hit by 5% share drop after results miss expectations

29 July 2016

Shares in Spanish drugmaker Grifols (GRF: MC) declined more than 5% by Friday afternoon versus two days earlier, after the company’s half-year earnings failed to meet market predictions.

The company, principally a producer of blood plasma-based products, has presented figures for the first half of 2016, which show that sales for the six months have totalled 1.95 billion euros ($2.17 billion), which is 2.7% higher than in the same period of 2015.

Grifols’ earnings before interest, taxes, amortization and depreciation (EBITDA) figure for 2016’s first half was 553.6 million euros, which is 1.8% below the 563.6 million euros expected by analysts and is 1.3% less than the EBITDA figure for the opening six months of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK